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Eeva K Salminen1*†, Krystyna Kiel3†, Geoffrey S Ibbott4†, Michael C Joiner5†, Eduardo Rosenblatt2†,
Eduardo Zubizarreta2†, Jan Wondergem2†, Ahmed Meghzifene2†

Abstract
The IAEA held the International Conference on Advances in Radiation Oncology (ICARO) in Vienna on 27-29 April
2009. The Conference dealt with the issues and requirements posed by the transition from conventional
radiotherapy to advanced modern technologies, including staffing, training, treatment planning and delivery,
quality assurance (QA) and the optimal use of available resources. The current role of advanced technologies
(defined as 3-dimensional and/or image guided treatment with photons or particles) in current clinical practice and
future scenarios were discussed.
ICARO was organized by the IAEA at the request of the Member States and co-sponsored and supported by other
international organizations to assess advances in technologies in radiation oncology in the face of economic
challenges that most countries confront. Participants submitted research contributions, which were reviewed by a
scientific committee and presented via 46 lectures and 103 posters. There were 327 participants from 70 Member
States as well as participants from industry and government. The ICARO meeting provided an independent forum
for the interaction of participants from developed and developing countries on current and developing issues
related to radiation oncology.
Introduction
ICARO: Advancing Radiation Oncology

All countries are facing an increased demand for health
services. In cancer care, there are more expensive
demands in diagnosis and treatment, including radiation
therapy, and systemic therapies. Radiation therapy is a
cost-effective method of treating cancer, yet it is unavailable in many low income countries throughout the
world. In high income countries, the ratio of treatment
machines to population may be as high as six per million individuals, but in many low and middle income
(LMI) countries, the ratio may be as low as one per 1070 million individuals. Twenty IAEA Member States
have no radiotherapy services at all and many lowincome countries have only basic equipment and often
few trained and qualified staff, for which there is a global shortage.
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The ICARO meeting provided an overview of topics
and issues facing the modern radiation oncologist with
an emphasis on advanced technologies and covering
topics as shown in Table 1. Invited speakers were prominent in the field, many with experience in LMI countries. Parallel sessions were held on topics specific for a
subset of the audience (medical physicists and radiation
oncologists) along with side events to discuss very specific issues such as QA in clinical trials and collaboration
with commercial companies. Summaries of individual
sessions are highlighted in the text.
Conclusions based on interaction and discussion
between participants focused on inadequacies of current
systems:
• There are many low income countries with no or
very basic diagnostic and treatment facilities.
• Low and middle income (LMI) countries have an
increasing number of cancer patients who present with
advanced stage disease, with few radiotherapy facilities.
Palliative treatment is common, but there are an
increasing number of potentially curable patients.
• Demand for radiotherapy services in LMI countries
will increase dramatically over the next 20 years.

© 2011 Salminen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Table 1 Overview of ICARO programme topics
Main topic

Advanced techniques (*) in teletherapy

Clinical sessions/clinical practice

Advances in chemo-radiotherapy in cervical and head-and-neck cancer
Current trends in brachytherapy
Radiotherapy in paediatric oncology
Reducing late toxicities
Altered fractionation

Training sessions/educational

How to set up a QA programme?
Commissioning and implementing a QA programme for new technologies
Transition from 2D to 3 D CRT and IMRT
Training, education and staffing: evolving needs/getting ready to transition to the new technologies
Cost and economic analysis in radiation oncology

Planning new activities

PACT meeting with manufacturers of diagnostics and radiotherapy equipment
Global quality improvement for clinical trials in radiation oncology

Controversial topics and debates

Co-60 - no time for retirement?
IMRT-are you ready for it?
Do we need proton therapy?

(*) For the purposes of this report, “advanced technologies” include 3-D conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT),
image-guided radiation therapy (IGRT), adaptive radiation therapy (ART), respiratory-gated radiation therapy (RGRT), particle radiation therapy, and image-guided
brachytherapy (IGBT) in all aspects; planning, treatment delivery, and quality assurance.

Diagnostic Imaging Requirements

Many successes in the treatment of cancer with radiation therapy are related to earlier diagnosis, a multidisciplinary approach to cancer diagnosis and treatment, and
more precise delivery of radiation therapy. Recent
advances in radiation therapy planning and delivery
allow improved normal tissue sparing and escalation of
the tumour dose compared to conventional techniques
(2D RT). These improvements require precise definition
of the tumour target, especially when three-dimensional
conformal radiation therapy (3D-CRT) and intensitymodulated radiation therapy (IMRT) are under consideration. Often this requires the use of dedicated
computed tomography (CT) scanning, which can be
integrated into treatment planning software. X ray exposure associated with extra imaging must be considered.
There is a general increase of diagnostic X ray exposure
worldwide in health care. The risks of radiation exposure in radiation treatment planning may be mitigated
by requirements for precise treatment delivery, and
developments in CT equipment may help reduce this
exposure.
Current role of cobalt-60

A debate was held regarding the utility of cobalt-60 teletherapy in routine practice. Cobalt-60 units have traditionally been “friendlier” treatment machines to place in new
low-resource departments with regards to cost, the training
required, treatment delivery, planning, and maintenance
[1,2]. However, the production cost of cobalt-60 sources is
increasing and there are heightened security concerns.
Modern sophisticated cobalt machines are more costly,
reflecting increasing pricing. At the same time, there has
been a relative decrease in the cost of small, single-energy
linear accelerators (linacs), making the two modalities

roughly comparable when combining initial and ongoing
costs. Cobalt-60 sources must be replaced every 5-6 years,
requiring disposal of the old sources (an increasingly costly
and logistically difficult problem) and this expense must be
weighed against cost, commissioning, training, and maintenance of a linac which has a useful lifespan of 10-12 years.
QA programmes are more complex for linac units. In
some LMI countries, the frequent lack of stable electrical
power can interfere with the smooth operation of linacs.
Service personnel may have to travel long distances, and
parts may not be readily available. Frustrations were
expressed with expensive and delicate equipment that was
rendered unusable by simple problems, especially when
requirements for infrastructure, staff training and maintenance were not initially recognized.
The current and emerging need for teletherapy units
in developing countries cannot be met by cobalt
machines alone. Selecting the right equipment should be
mainly based on local radiotherapy experience and casemix, as well as on financial, technical and human
resources available. Many LMI countries may benefit
from the use of both cobalt units and linacs with use
based on complexity of treatment.
Conclusion:
• There remains a role for cobalt teletherapy in LMI
countries. New technical developments may allow
the introduction of highly-conformal treatment techniques with cobalt but this increases the cost to the
level of medical linear accelerators.

Implementation of advanced technologies

A series of keynote lectures discussed the underlying
hypothesis for the use of advanced technologies in

Salminen et al. Radiation Oncology 2011, 6:11
http://www.ro-journal.com/content/6/1/11

radiation therapy, discussing the assumption that
improved dose distribution leads to improvement in
clinical outcomes.
New treatment technologies are evolving at a rate
unprecedented in radiation therapy, paralleled by
improvements in computer hardware and software. The
challenging use of highly precise collimators in the
IMRT setting, small fields, robotics, stereotactic delivery,
volumetric arc therapy and image guidance has brought
new challenges for commissioning and QA. Existing QA
guidelines are often inadequate for some of these technologies. New QA procedures are needed and are under
development. In the meantime, the existing paradigm of
commissioning followed by frequent QA should continue, with attention paid to the capabilities offered by
the new technologies. Risk management tools should be
adapted from other industries to help focus QA procedures on where they can be most effective.
These techniques allow assessment of changes in the
tumour volume and its location during the course of
therapy (interfraction motion) so that re-planning can
adjust for such changes in an adaptive radiotherapy process. Some target volumes move during treatment due
to respiration (intrafraction motion), especially those in
the lung, liver and pancreas. Advanced techniques for
compensating for such motion are already commercially
available and include respiratory gating, active breathing
control and target tracking.
The speakers advised to approach the implementation
of the new technologies with caution. If the identification of target tissues is uncertain when margins around
target volumes are tight, the likelihood of geographic
misses or under-dosing of the target increases. Movement of the target with respiration or for any reason
during treatment increases the risk of missing or underdosing the target. Since in some instances IMRT uses
more treatment fields from different directions, its use
may increase the volume of normal tissue receiving low
doses which might lead to a higher risk of secondary
cancers. With the introduction of any advanced technology, such as IMRT and IGRT, data should be collected
prospectively, to allow a thorough evaluation of costeffectiveness and cost-benefit [3,4].
A debate on IMRT: Are you ready for it? brought
together panel members who represented various views
from all regions of the world, including high and LMI
countries. A modality such as IMRT offers the theoretical potential to increase radiation dose to tumour target
volumes while sparing normal tissues. Health economics
was identified as a key motivator in the adoption of
IMRT. There is still a lack of randomized trials supporting robust evidence of clinical benefit of IMRT in many
tumour sites. There is little prospective data demonstrating that IMRT provides clinical benefit other than
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improved dose distribution [5]. Unexpected toxicities
and recurrences have been reported in the literature [3].
In the USA, where such trials could be done, there is
great difficulty recruiting patients to the non-IMRT arm
because hospitals promote IMRT in order to stay economically competitive. In Europe, IMRT is used somewhat less, with figures for Belgium being approximately
50% and the UK less than 50%. In India and South
Africa, the figure drops to 25%. Comparative case series
[6,7] and some phase-III trials [8,9] have been completed in the USA, Europe and Asia. The overall conclusion from these trials is that there is evidence of
reduced toxicity for various tumour sites by the use of
IMRT. The evidence regarding local control and overall
survival is generally inconclusive [5].
Advanced technologies of radiation treatment such as
IMRT require optimal immobilization and image guidance techniques. There was debate as to whether
image guidance was always required with IMRT to
ensure accurate delivery. Whether image guidance was
necessary daily was also debated and this may be necessary in specific cases, such as when immobilization is
not optimal or when hypofractionation is used. Other
techniques to control organ motion during treatment
such as respiratory-gating and breath-hold techniques
may be necessary when reduced target volumes are
considered.
A survey on IMRT conducted in the USA [10] determined that the three main motivators for implementing
this modality were normal tissue sparing (88%), allowing
dose-escalation (85%) and economic competition (the
desire to remain competitive) (62%). In addition, 91% of
non-users planned to adopt IMRT in the future.
Image Guided Radiation Therapy (IGRT) can be
defined as increasing the radiotherapy precision, by frequent imaging the target and/or healthy tissues just
before treatment and acting on these images to adapt the
treatment [11]. There are several image-guidance options
available: non-integrated CT scan, integrated x-ray (kv)
imaging, active implanted markers, ultrasound, singleslice CT, conventional CT or integrated cone-beam CT.
A survey on IGRT in the USA [12] revealed that the
proportion of radiation oncologist self-declared users of
IGRT was 93.5%. However, when the use of megavoltage
(MV) portal imaging was excluded from the definition
of IGRT, the proportion using IGRT was 82.3%. Among
IGRT users, the most common disease sites treated are
genitourinary (91.1%), head and neck (74.2%), central
nervous system (71.9%), and lung (66.9%).
Conclusions:
• Robust clinical trials are necessary to demonstrate
the benefits of advanced technologies before they are
adopted into widespread use.
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• A new and unproven technology should not be
universally adopted as a replacement for established
proven technologies.
• LMI countries should avoid the risk that by hasty
implementation of new technologies, patients would
no longer have access to established methods of
treatment.

Introduction of advanced technologies: the radiation
oncologist perspective

It was noted that the implementation of advanced radiotherapy technologies tends to distance the physician from
the patient, a trend that needs to be consciously counterbalanced by a more personal and holistic approach. In
addition, it makes it more and more difficult to intuitively
understand the relationship between the radiation fields
and the patient’s anatomy. Whereas with 3D conformal
radiation therapy, the physician can rely on port films to
assess the irradiated volume, with IMRT the physician
must rely on tools such as computer simulations and
dose-volume histograms (DVH). Users of advanced technologies should be cautioned not to allow themselves to
become too dependent upon the technology itself. It was
also recommended that advanced technologies such as
IMRT and IGRT should not be acquired until physicians
and hospital staff are fully experienced with advanced
treatment planning techniques in 3D conformal therapy.
Modern 3D approaches including IMRT introduce new
requirements in terms of understanding of axial imaging
and tumour/organs delineation. Recent literature points
to an uncertainty level at this stage known as “interobserver variations”. Efforts continue to harmonize the
criteria with which tumours, organs and anatomical
structures are contoured and how volumes are defined.
Introduction of advanced technologies: the medical
physics perspective

The introduction of IMRT and stereotactic radiation
therapy procedures brings special physics problems. For
example, it is required that calibrations be performed in
small fields, for which the dosimetry is challenging, and
no harmonized dosimetry protocol exists. Use of the
correct type of dosimeter is critical, and errors in measurement can be substantial. Several new treatment
machines provide radiation beams that do not comply
with the reference field dimensions given in existing
dosimetry protocols complicating the accurate determination of dose for small and non-standard beams.
The introduction of highly precise collimators in the
IMRT setting, small fields, robotics, stereotactic delivery,
volumetric arc therapy and image guidance has brought
new challenges for commissioning and QA. The existing
QA guidelines are often inadequate for the use of some
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of these technologies. New QA procedures are needed
and are under development. In the meantime, the existing paradigm of commissioning followed by frequent QA
should continue, with attention paid to the capabilities
offered by the new technologies. Risk management tools
should be adapted from other industries, to help focus
QA procedures on where they can be most effective [13].
It was observed by several speakers that IMRT requires
increased attention to physics and dosimetry, more
equipment, training and technical support, and more
time for quality assurance. Specific issues mentioned
included the critical need for accurate calibration of the
position of multi-leaf collimator leaves, and the precise
modelling of radiation dose distributions especially in the
penumbra region produced by MLC leaves. The veracity
of data transfer from the treatment plan to the treatment
machine is critical whether it be by electronic or manual
means, and should be included in QA programmes.
Fractionation

Advanced technologies provide an opportunity for the
acceleration of treatment without excessive risk to normal tissue [3]. Hypofractionated treatments are more
convenient to patients and caregivers. But convenience
is not enough to make hypofractionation a mainstay
treatment. Much of this subject is still surrounded by
ongoing controversy. The avoidance of dreaded late
effects of hypofractionation obviously cannot be confirmed without long and careful follow-up [14].
In curative and palliative treatment, several trials of
hypofractionation in common cancers have shown comparable clinical outcomes to conventional fractionation.
These schedules vary for different diseases with fractions
>2 Gy given daily to once weekly. Common cancers,
such as breast cancers, can be successfully treated in
three weeks rather than in five weeks [15]. Advanced
technology radiation therapy (3D CRT and IMRT) may
provide an opportunity for the study of tissue tolerance
as high doses per fraction can be delivered to small
tumour volumes while normal tissues receive conventional fractionated radiation.
Investigators treating common diseases such as prostate and breast cancer are using non-ablative hypofractionation in patients with curable tumours. This strategy
tends to be well received in environments where the
cost-savings associated with fewer fractions is important.
In some cases, such hypofractionation has a biological
rationale for improving the therapeutic ratio [14].
Conclusions:
• There is significant published experience with the
use of hypofractionated regimens in breast, [15,16]
prostate [17,18] brain/body [19] and palliative
radiotherapy.
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• The use of hypofractionated regimens can be particularly useful in limited-resource centres overloaded
with large number of patients.

Current role of proton therapy

The dosimetric advantage of charged-particle beam
radiotherapy derived from the Bragg peak was emphasized. Protons and other particles have been used for
decades for ocular melanomas, base of skull tumours,
and brain tumours where radiation dose escalation
using photons was not possible due to normal tissue
constraints. The first hospital-based proton facility was
opened in Loma Linda (USA) in 1999 [20]. Since then,
over 30 particle-based facilities have opened and another
30 are in the planning stages worldwide, primarily for
the treatment of cancer patients. Until recently, the significant capital expenditure required for the establishment of a proton facility has limited the availability of
this form of radiation therapy in many areas of the
world. This modality is expensive, time consuming, and
requires special expertise. The cost of treatment is significantly higher than conventional 3D-CRT.
During the ICARO meeting, a debate addressed the
question: Is there a need for proton therapy? Proponents
and opponents considered the following three propositions: (1) Proton dose distributions with currently available equipment are likely to be of real benefit to
patients; (2) On the basis of clinical evidence, protons
should be made available for radical radiotherapy to
many more patients; and (3) Further technological
developments will make proton therapy more cost
effective.
The speakers described the advantages offered by
proton beams, such as increased conformality of dose
distributions to target volumes and lower doses to nontarget tissues. The speakers provided examples of exquisitely-shaped dose distributions that can be achieved
with both photon IMRT and with spot-scanned protons.
It was mentioned that the improved dose distributions
with protons might offer significant benefits to paediatric patients, although the benefits might require some
years to become detectable and may not yet be readily
measureable. No benefit has been demonstrated in the
treatment of prostate cancer, including following completion of one randomized trial [21] although proton
therapy appears at least to match the high success rates
and low toxicity available with photon IMRT [22,23].
Future advances in proton therapy equipment and technologies are expected to provide even greater benefits
through improved dose distributions and patient
throughput, but challenges in standardizing calibrations,
treatment parameters, and the relative biological effectiveness must be addressed first. Proton treatment of
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cancer patients should be done preferably within clinical
studies for collecting data, which allows clear comparison with conventional photon treatment, thereby defining the role of proton therapy precisely within radiation
oncology. Reported biochemical disease-free survival
rates after carbon ion radiotherapy appear higher than
with modern photon IMRT and proton RT especially
for patients with high-risk prostate cancer [24].
Slater and co-workers [23] report a 5-year NED rate
of 57% while a 5-year NED rate of 51% was reported for
conventional RT with photons [25].
Photon IMRT yields a biochemical DFS rate of 81% at
3 years, whereas severe toxicity rates to the genitourinary system and the rectum are higher as compared with
the rates reported by Akakura and co-workers with carbon ions (10% vs. 1.4%) [24].
Conclusions:
• Physical dose distributions of proton beams are
superior to those of photons
• The cost of establishing and maintaining proton
facilities is significant
• Clinical trials are underway and over the next several years an increased amount of clinical data will
become available
• The question of whether the clinical gains from
proton therapy will outweigh the costs is an unresolved issue.

Brachytherapy

The session on brachytherapy highlighted recent advances
in this modality of radiation therapy. In the past,
brachytherapy was carried out mostly with Radium (226Ra)
sources. Currently, use of artificially produced radionuclides such as 137Cs, 192Ir, 60Co, 198Au, 125I, and 103Pd has
rapidly increased.
Brachytherapy is an essential component of the curative treatment of cervical cancer (a very common disease
in many LMI countries) and cannot be replaced by
other modalities in this setting. High dose-rate (HDR)
brachytherapy is preferable to low dose-rate (LDR) for
departments with limited resources that treat a large
number of patients with cervical cancer. New systems
using a miniaturised 60 Co source are becoming very
popular [26-29]. This is due to the fact that 60Co based
HDR systems require source replacement approximately
every 5 years while 192 Ir requires replacement every
3-4 months. This represents a significant advantage in
terms of resource sparing, import of radioactive sources
into countries, regulatory requirements and additional
workload [30].
Over the last decade developments in imaging, computer processing and brachytherapy systems and
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applicators have made possible to implement threedimensional treatment planning based on cross sectional
imaging with the applicators in place using CT or MRI.
This has been successfully developed for the brachytherapy of cervical cancer [31-33].
Individual departments in low-middle income countries should carefully weight the advantages and disadvantages of adopting this system which implies expenses
in terms of applicators and requires readily available
MRI services dedicated to the brachytherapy unit or
department.
In prostate cancer, excellent long-term tumour control
can be achieved with brachytherapy, and this approach
is considered a standard treatment intervention associated with comparable outcomes to prostatectomy and
external beam radiotherapy for patients with clinically
localized disease [34]. In low-risk disease patients, seed
implantation alone (monotherapy) achieves high rates of
biochemical tumour control and cause-specific survival
outcomes. For those with intermediate risk and selected
high-risk disease, a combination of brachytherapy and
external beam radiotherapy is commonly used.
In the treatment of prostate cancer, the radioactive
sources can be implanted permanently using 125I seeds
[35] or as a fractionated temporary implant using a high
dose-rate stepping source. Although the experience with
seed implantation is more extensive and the results
mature [36], the use of HDR brachytherapy as monotherapy or combined with external beam therapy is becoming
more popular in radiotherapy departments that already
have a HDR brachytherapy device, thus avoiding the
costs and procedures of importing 125 I seeds for each
individual patient [37,38]. HDR brachytherapy offers several potential advantages over other techniques. Taking
advantage of an afterloading approach, the radiation
oncologist and physicist can more easily optimize the
delivery of radiation therapy to the prostate and reduce
the potential for under-dosage ("cold spots”). Further,
this technique reduces radiation exposure to the care
providers compared to permanent seed implantation.
Current approaches are employing HDR monotherapy
for intermediate risk patients avoiding the need for supplemental external beam radiotherapy [39].
Both approaches are time/effort consuming and require
careful attention to technical detail. An imaging method
(commonly trans-rectal ultrasound) has to be used during seed or needle implantation. The procedures require
attention to accurate dosimetry and normally there is a
“learning curve” for the whole brachytherapy team.
The introduction of HDR brachytherapy as a treatment modality carries with it additional concerns related
to QA and radiation protection. The very principle of
HDR brachytherapy is based on working with a very
high activity radiation source, and short treatment
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times. Therefore, all centres implementing HDR brachytherapy must establish a written policy on QA and
pay utmost attention to basic principles of radiation
protection.
HDR treatments dramatically increase the physician
and physicist resources that must be allocated to brachytherapy while reducing the needs for inpatient hospital beds. The relative cost and availability of these
resources should be compared, and the cost-savings,
compared with the cost of amortizing the capital investment required and the cost of source replacement and
machine maintenance [40].
Education and training

An important theme echoed by several speakers and the
audience was the global shortage of skilled professionals.
It was noted that while short-term and local solutions
have been devised, there was a need for a long-term
strategy to produce trainers and educators who could
increase the supply of adequately trained staff. Training
must be adapted to both the working environment and
the level of complexity of the available technology; little
benefit is derived by a trainee or the trainee’s institution
when the education addresses a technology not available
in his or her own country.
There is clearly a role for networking on the national
and regional levels to support education networks. The
role of the IAEA in education and training through
national and regional training courses and development
of teaching materials and syllabi was recognized.
Conclusions:
• There is a worldwide shortage of qualified radiotherapy professionals
• Specialized education and training must be provided to meet this demand.

Cost considerations

In the delivery of routine radiotherapy, most expenditure is in personnel costs, followed by equipment costs
and depreciation. Each institution has its own requirements for equipment and personnel. These requirements are based on the type and stages of encountered
cancers ("case-mix”), the type of equipment and facilities
availability, local work practices, and method of financing, maintenance costs, and down-time and life cycle of
treatment machines. Many countries have observed the
cost of radiation therapy delivery to have increased
annually.
The IAEA has developed a cost estimator [41] which
takes into account potential workload based on cancer
incidence and staging, overhead and indigenous costs of
personnel and facilities, in addition to equipment costs.
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The costs of a cobalt-60 machine when including ultimate source disposal, has become similar to a low
energy linear accelerator, but training, personnel, and
maintenance costs are lower and reliability is higher.
Cost-effectiveness analysis (CEA) is a form of economic
analysis that compares the relative costs and outcomes
(effects) of two or more courses of action [42]. Costeffectiveness analysis is distinct from cost-benefit analysis,
which assigns a monetary value to the measure of effect
[43]. Cost-effectiveness analysis is often used in the field of
health services, where it may be inappropriate to monetize
health effect. Typically, CEA is expressed in terms of a
ratio where the denominator is a gain in health from a
measure (years of life) and the numerator is the cost associated with the health gain. The most commonly used outcome measure is quality-adjusted life years (QALYs) [44].
Cost effectiveness can be measured in gain in quality
adjusted life years (QALY), cost per QUALYs, cost per
year of life gained or cost per loco-regional failure
avoided.
When assessing the usefulness of newer advanced
technologies, cost effectiveness can be measured several
ways:
Is the number of patients to whom services are delivered increased? (Improved access). Are cure-rates
increased? (improved curability). Is toxicity significantly
reduced? (Improved therapeutic index) What is the ultimate objective for the introduction of a new technology?
And what are its cost implications?
Systematic studies of the newer technologies seem
required following the methodologies of health technology assessment and the dissemination of the results in a
form that is accessible to clinicians, mangers and the
public. Unfortunately, much of the evidence indicates
that it is difficult to influence practitioners simply by
producing and disseminating information.
Although extremely important, education and training
costs are not usually considered in these formulas. Cost
effectiveness can often be improved by optimal use of
conventional technologies and better work practices. For
instance, hypofractionation can increase patient
throughput while maintaining the same outcome in
selected indications.
Radiotherapy services in LMI countries need high level
government commitment to mobilize the necessary
funds of approximately $5-6 million necessary to establish a basic cancer centre. Such projects, when completed, take at least 5 years to make a noticeable
difference in the health care system as a whole.
Conclusions:
• ICARO speakers and panellists emphasized that
each country should have a comprehensive plan for
cancer control.
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• The value of advanced technology must be
assessed relative to the indigenous needs and structures of the country. It is important that radiation
oncology be part of health planning for a country/
community, particularly when there is competition
for health financial resources.
• In LMI countries, service and maintenance must
be considered. Service and spare parts are often not
readily available and must come from great distances. In the curative treatment of cancer, the
impact of equipment ‘down-time’ may be significant
and measurably detrimental.

New activities launched at ICARO

Two sessions focused on completely new activities
which are to be facilitated by the IAEA in the future.
1. Quality assurance of international clinical trials

A session was held which reported on the objectives and
current status of a working party that is addressing
improvements to the implementation of international
clinical trials. Harmonization of QA requirements and
the streamlining of facility questionnaires were discussed, as were the requirements for databases and digital data submission for improved record collection and
analysis. This global working party will meet several
times a year to continue the process of analysis and
improvement of international clinical trials.
2. PACT and manufacturers

A side-meeting with manufacturers of diagnostic and
radiotherapy equipment was hosted by IAEA’s Programme
of Action for Cancer Therapy (PACT) and the Division of
Human Health (NAHU). This meeting was convened due
to the IAEA’s unique and leading role in assisting Member
States in the development of cancer therapy, strengthening
collaboration with manufacturers in providing equipment
that is safe, affordable and technically suitable for developing country conditions. An advisory group was established
to continue the process of discussions between the IAEA,
manufacturers and users [45].

Conclusions
Demand for radiotherapy services in LMI countries will
increase significantly in the next 20 years. Many Member States are still without or with only very basic radiotherapy facilities. There is a shortage of qualified
radiation oncologists, medical physicists, dosimetrists,
radiation therapists, nurses, and maintenance engineers
in the developing world. Education and training must be
provided to meet this demand and training must be ideally adapted to the available equipment and disease
profiles.
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Since there is competition for health care resources
and equipment, technical support has to be consistent
with the health system infrastructure of each country to
keep radiation treatment affordable, safe and of good
quality. In LMI countries, service and maintenance are
often not available and must come from afar. This
needs to be recognized when purchasing any equipment
or technology.
The conference gave delegates of LMI countries an
opportunity to assess new technologies relative to their
own situations. Many aspects of advances in radiation
oncology were covered and evaluated, ranging from the
role of basic technology to how to upgrade and adapt
departments to advanced technology. The benefits,
implications, pitfalls, economics, risks, and practicalities
of implementing advances from a variety of viewpoints
were discussed.
Recommendations

• Basic radiation therapy services at a minimum
should be made available to all patients with cancer
who need them.
• Education and training programmes to enable
good quality radiation therapy services need to be
developed and job opportunities offered with adequate salary levels to retain staff.
• Advanced technologies in radiation therapy should
not be universally adopted until the following conditions are met:
- A need for advanced technology exists (i.e.
patients with curative potential)
- Experience with 3D conformal radiation therapy and advanced treatment planning exists
before implementation of more advanced
technologies
- Adequate imaging services are available
- Studies demonstrate a universal advantage to
each aspect of advanced technology, either in
improving local control or in reducing toxicity
- Personnel have adequate training in planning,
implementation, and QA in advanced technology
- Continuous medical education system is in
place.
- An adequate QA/QC programme is in place.
• Clinical studies should be undertaken to demonstrate clinical and cost-effective benefits to the advanced
technologies.
• Each country must clearly define which cancer
outcomes are expected to be improved by the introduction of advanced technologies.
• New technologies such as IMRT offer theoretical
advantage in radiation dose distribution. Presently,
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there is a paucity of evidence that IMRT can
improve tumour-related outcomes, and clinical trials
are clearly needed.
• Despite the growing use of protons in various sites
including prostate cancer, proton therapy must remain
under scrutiny until it has proven itself cost-effective.
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